HUT68021A - Improved activating process of recombinant proteins - Google Patents

Improved activating process of recombinant proteins

Info

Publication number
HUT68021A
HUT68021A HU9200548A HU9200548A HUT68021A HU T68021 A HUT68021 A HU T68021A HU 9200548 A HU9200548 A HU 9200548A HU 9200548 A HU9200548 A HU 9200548A HU T68021 A HUT68021 A HU T68021A
Authority
HU
Hungary
Prior art keywords
recombinant proteins
activating process
amino acids
improved activating
helper sequences
Prior art date
Application number
HU9200548A
Other languages
English (en)
Other versions
HU214881B (hu
HU9200548D0 (en
Inventor
Rainer Rudolph
Carola Dony
Dorothea Ambrosius
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6425597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUT68021(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of HU9200548D0 publication Critical patent/HU9200548D0/hu
Publication of HUT68021A publication Critical patent/HUT68021A/hu
Publication of HU214881B publication Critical patent/HU214881B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Dental Preparations (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Adhesive Tapes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9200548A 1991-02-21 1992-02-20 Rekombináns proteinek javított aktiválási eljárása HU214881B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4105480A DE4105480A1 (de) 1991-02-21 1991-02-21 Verbesserte aktivierung von rekombinanten proteinen

Publications (3)

Publication Number Publication Date
HU9200548D0 HU9200548D0 (en) 1992-04-28
HUT68021A true HUT68021A (en) 1995-04-04
HU214881B HU214881B (hu) 1998-07-28

Family

ID=6425597

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9200548A HU214881B (hu) 1991-02-21 1992-02-20 Rekombináns proteinek javított aktiválási eljárása

Country Status (20)

Country Link
US (1) US5578710A (hu)
EP (1) EP0500108B1 (hu)
JP (1) JP2528232B2 (hu)
KR (1) KR950014493B1 (hu)
AT (1) ATE144284T1 (hu)
AU (1) AU641081B2 (hu)
CA (1) CA2061569C (hu)
CZ (1) CZ282744B6 (hu)
DE (2) DE4105480A1 (hu)
DK (1) DK0500108T3 (hu)
ES (1) ES2093122T3 (hu)
FI (1) FI106029B (hu)
GR (1) GR3021395T3 (hu)
HU (1) HU214881B (hu)
IE (1) IE920276A1 (hu)
IL (1) IL101024A (hu)
MX (1) MX9200709A (hu)
NO (1) NO300329B1 (hu)
NZ (1) NZ241570A (hu)
ZA (1) ZA921230B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
MXPA03002046A (es) 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
CA2452582C (en) 2001-07-11 2013-01-22 Maxygen Holdings, Ltd. G-csf conjugates
AU2003210052A1 (en) 2002-03-20 2003-09-29 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
WO2006055260A2 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
AR064235A1 (es) * 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
EP2185689A2 (en) 2007-08-09 2010-05-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
ES2639398T3 (es) 2010-03-04 2017-10-26 Pfenex Inc. Método para producir proteína de interferón recombinante soluble sin desnaturalización
JP5964757B2 (ja) 2010-03-17 2016-08-03 ラチオファーマ ゲーエムベーハー 生物学的活性型組換えヒトｇ−ｃｓｆを得るための方法
NZ603033A (en) 2010-04-01 2014-06-27 Pfenex Inc Methods for g-csf production in a pseudomonas host cell
EP2880169B1 (en) * 2012-08-02 2017-05-17 F. Hoffmann-La Roche AG Method for producing monomeric and multimeric molecules and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
DK55685A (da) * 1985-02-07 1986-08-08 Nordisk Gentofte Enzym eller enzymkompleks med proteolytisk aktivitet
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US5082775A (en) * 1984-05-11 1992-01-21 Berlex Laboratories, Inc. Efficient process for isolating insoluble heterologous protein using non-ionic detergents
US4948729A (en) * 1985-03-25 1990-08-14 Cetus Corporation Production of soluble recombinant proteins
US4783415A (en) * 1985-03-28 1988-11-08 Meiji Seika Kabushiki Kaisha Gene coding for signal peptides and utilization thereof
US5087564A (en) * 1985-06-20 1992-02-11 Monsanto Company Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3636903A1 (de) * 1985-12-21 1987-07-02 Hoechst Ag Fusionsproteine mit eukaryotischem ballastanteil
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
AU605291B2 (en) * 1987-03-20 1991-01-10 Micromet Ag Process for the purification of recombinant polypeptides
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH03503596A (ja) * 1987-06-24 1991-08-15 ノボ・ノルディスク　エー／エス 蛋白質若しくはポリペプチドの調製方法、該ポリペプチドをコードするｄｎａ配列、該ｄｎａ配列およびポリペプチドを有する微生物および該ポリペプチドの薬学的製剤としての利用
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
ZA901719B (en) * 1989-03-19 1991-01-30 Akzo Nv Hog cholera virus vaccine and diagnostics
US5191063A (en) * 1989-05-02 1993-03-02 University Of Medicine And Dentistry Of New Jersey Production of biologically active polypeptides by treatment with an exogenous peptide sequence
US5115102A (en) * 1989-07-21 1992-05-19 Monsanto Company Variant proteins and polypeptides possessing enhanced affinity for immobilized-metal affinity matrices
AU8417091A (en) * 1990-08-20 1992-03-17 Novo Nordisk A/S Biologically active compound, a process for the preparation thereof and use of the same

Also Published As

Publication number Publication date
FI106029B (fi) 2000-11-15
NO300329B1 (no) 1997-05-12
KR950014493B1 (ko) 1995-12-02
DK0500108T3 (da) 1997-03-24
AU1094892A (en) 1992-08-27
NO920671D0 (no) 1992-02-20
NZ241570A (en) 1994-09-27
CA2061569C (en) 2000-10-24
EP0500108B1 (de) 1996-10-16
CA2061569A1 (en) 1992-08-22
IL101024A0 (en) 1992-11-15
GR3021395T3 (en) 1997-01-31
KR920016464A (ko) 1992-09-24
IE920276A1 (en) 1992-08-26
JPH05244977A (ja) 1993-09-24
US5578710A (en) 1996-11-26
JP2528232B2 (ja) 1996-08-28
FI920742A (fi) 1992-08-22
MX9200709A (es) 1992-09-01
EP0500108A2 (de) 1992-08-26
IL101024A (en) 1996-06-18
CZ282744B6 (cs) 1997-09-17
EP0500108A3 (en) 1993-04-07
ZA921230B (en) 1992-11-25
NO920671L (no) 1992-08-24
FI920742A0 (fi) 1992-02-20
DE59207351D1 (de) 1996-11-21
HU214881B (hu) 1998-07-28
AU641081B2 (en) 1993-09-09
DE4105480A1 (de) 1992-08-27
ES2093122T3 (es) 1996-12-16
HU9200548D0 (en) 1992-04-28
ATE144284T1 (de) 1996-11-15
CS49992A3 (en) 1992-09-16

Similar Documents

Publication Publication Date Title
HUT68021A (en) Improved activating process of recombinant proteins
DE69033040D1 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
ATE123520T1 (de) Kex2-endoprotease und verfahren zu ihrer herstellung.
CA2005502A1 (en) Somatotropin analogs
FI880017A (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
DE3688324D1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
AU669483B2 (en) Nucleotide sequences and resistance proteins cycloheximide
DK0652903T3 (da) Nyt humant rekombinant gammainterferon
DE68907635D1 (de) Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
DE3852105D1 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
FR2635527B1 (fr) Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
DE68923496D1 (de) Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression.
IT8719551A0 (it) Plasmidi ricombinanti utili perl'espressione in bacillus di proteine eterologhe.
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE69534738D1 (de) Leukocyten-aktivierender Faktor
GB9604518D0 (en) Novel compounds
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees